Acrux Limited (ACR.AX)
Acrux Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in West Melbourne, VIC, AU. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $5.3M. Its beta of 0.99 implies it has historically moved less than the broad market.
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Acrux Limited is most often compared with the following Healthcare names: